Business
JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA
JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL ...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\nJUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nCanada NewsWire\n\n\nThe commercial launch is planned for June 2027 subject to Health Canada approvalBOUCHERVILLE, QC, April 9, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (\"LSL Pharma\" or the \"Company\"), a Canadian integrated pharmaceutical company, today announced the signing of a binding term sheet with Instapill Private Limited (Instapill) for the supply of private label Loratadine 10 mg rapid dissolve tablets (RDT) to Canadian retailers. The product is bioequivalent to Claritin RDT and positions LSL Pharma in the large, recurring over-the-counter (OTC) allergy category, addressing strong and growing consumer demand. The Canadian OTC allergy category is estimated at $60 million and growing at 8% per year.This agreement builds on the momentum generated by Juno OTC's initial collaboration with Instapill for Loperamide 2 mg RDT, equivalent to Imodium RDT, which is now widely distributed under private label across major Canadian retailers and delivering robust commercial performance.Through this strategic partnership with Instapill, a global leader in rapid dissolve technology, LSL Pharma, via its private label division Juno OTC, secures access to a pipeline of innovative dosage formats designed for convenience, speed, and enhanced patient compliance. The Company is actively advancing additional OTC RDT products with the goal of building a broad, high-volume portfolio across multiple therapeutic categories.\"Signing this term sheet with Instapill is a testament to Juno OTC's execution capabilities and accelerates our growth trajectory in the consumer health space,\" said Francois Roberge, President & Chief Executive Officer of LSL Pharma. \"The strong market adoption of our Loperamide RDT has validated our commercialization model and confirms the potential of o...